Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

POLYTROP

Financiado

Development of Novel Multimodal Dextran-Based Theranostic Tracers: Targeting Fib...

Development of Novel Multimodal Dextran-Based Theranostic Tracers: Targeting Fibroblast Activation Protein as Proof of Concept According to WHO, cancer is a leading cause of death worldwide, accounting for nearly 20 million new cases and 10 million deaths in 2020. This project addresses the development of a novel compound targeting the fibroblast activati... ver más

31/05/2025

"NCSR ""D"""

169K€

Presupuesto del proyecto: 169K€

Líder del proyecto

NATIONAL CENTER FOR SCIENTIFIC RESEARCH DEMOK... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Financiación concedida El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2023-05-11

HORIZON-WIDERA-2022-TALENTS-04-01: Fostering balanced brain circulatio... ExpectedOutcome:This action will build on the MSCA Postdoctoral Fellowships 2022 action (HORIZON-MSC...

I+D

Cerrada hace 2 años

0% 100%

1 Participantes

"NCSR ""D"""

169.33K€ | Lider

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

C2RTheranostics Exploring a click-to-release approach to uncage FAP-theranos... 176K€ Cerrado

PID2019-108352RJ-I00 AGENTES DE CONTRASTE PARA IRM BASADOS EN HIERRO(III) PARA LA... 182K€ Cerrado

QUIC-CONCEPT QUantitative Imaging in Cancer: CONnecting CEllular Processe... 16M€ Cerrado

EQC2018-004306-P LABORATORIO INTERDISCIPLINAR DEL CENTRO CIENTIFICO-TECNOLOGI... 240K€ Cerrado

RADIOBIO Deciphering the radiobiology of targeted radionuclide therap... 2M€ Cerrado

PID2019-110218RB-I00 ESTRATEGIAS BASADAS EN COMPLEJOS METALICOS PARA EL DIAGNOSTI... 97K€ Cerrado

Duración del proyecto: 24 meses Fecha Inicio: 2023-05-11
Fecha Fin: 2025-05-31

Líder del proyecto

NATIONAL CENTER FOR SCIENTIFIC RESEARCH DEMOK... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 169K€

Descripción del proyecto According to WHO, cancer is a leading cause of death worldwide, accounting for nearly 20 million new cases and 10 million deaths in 2020. This project addresses the development of a novel compound targeting the fibroblast activation protein, overexpressed in more than 90% of human epithelial cancers. It combines up to four imaging techniques (single-photon emission computed tomography, positron emission tomography, magnetic resonance, and optical imaging) and two therapeutic approaches (radionuclide therapy and boron neutron capture therapy (BNCT)). The novel compound is based on a dextran scaffold, which acts as a backbone for attachment of i) a FAP-inhibitor based on a quinoline structure, ii) a macrocycle chelator for complexation with Gadolinium, Technetium-99m, Rhenium-188, Gallium-68, and Lutetium-177 for imagining or radionuclide therapy, iii) carborane for BNCT and iv) fluorescent dye for optical imaging. The aim is to achieve a tailor-made combination of unique and versatile properties by adapting the multifunctional structure of the ligand compound throughout different imaging and therapeutic procedures using a simple and robust labeling protocol, exploiting the outstanding properties of each moiety and conferring our compound with precisely designed functionalities. The implementation and delivery of high-impact outcomes will be achieved following a well-defined route. The long-term objective of this project is to determine whether vial kits for imaging and therapy can be developed. The novel ligand will be synthesized following well-established methodologies and fully characterized by elemental analysis, IR, and NMR. Then, the radiolabeling procedures of the ligand with the radionuclides will be optimized, and a kit formulation will be developed. At the same time, the project will determine the inhibitory activities of the radiolabeled compounds and their applicability for in vivo imaging and radionuclide therapy in FAP-positive tumor-bearing mice.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores